NHS plans a 3-year phased rollout of obesity drug Mounjaro, targeting 250,000 patients with multiple health conditions.

The NHS plans a phased rollout of the obesity drug Mounjaro, also known as tirzepatide, over three years, targeting 250,000 patients. Initially, it will prioritize those with multiple health conditions linked to obesity. Clinical trials showed an average weight loss of 21% over 36 weeks with the drug, which also assists with blood sugar management. The National Institute for Health and Care Excellence will review the proposals before final guidance is issued.